A Second Psilocybin Group Therapy for the Treatment of Cancer-Related Anxiety in Partial Responders With Metastatic Cancer

Phase I single-group interventional study of a second psilocybin-assisted group therapy session in partial responders with metastatic cancer. Participants receive oral psilocybin with an optional booster on day 0, individual and group preparation and integration visits, and follow-up at 2, 3 and 6 months.

Primary aims are safety and tolerability; secondary assessments include efficacy on anxiety/distress (HADS), quality of life and standard safety monitoring including labs and ECG.